Study S000831

A Study Comparing Exposure of Semaglutide and Dapagliflozin Dosed Orally as Mono-components Versus in a Fixed-dose Combination

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05429593
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 152
Start: 2022-06-22
Primary completion: 2023-03-10
Lead sponsor: Novo Nordisk A/S
Conditions: Healthy Volunteers
Interventions: DRUG:Semaglutide; DRUG:Dapagliflozin; DRUG:Semaglutide/dapagliflozin
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1266-4254; OTHER:2022-500007-52-00

Registered primary outcomes

AUC0-24h,sema,ss: area under the semaglutide plasma concentration-time curve during a dosing interval (0 to 24 hours) at steady state [From 0 to 24 hours on day 49 and 84 in Part 1]
AUC0-24h,dapa,ss: area under the dapagliflozin plasma concentration-time curve during a dosing interval (0 to 24 hours) at steady state [From 0 to 24 hours on day 49 and 98 in Part 2]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.